Protacs


The 357-page report ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics, 2020-2030’ focuses on the small molecule degraders including specific and non-genetic IAP-dependent protein erasers (SNIPERs), proteolysis targeting chimeras (PROTACs), lysosome targeting chimeras (LYTACs), endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. The report highlights the capabilities of protein degraders and major market players involved in the evaluation. It is worth mentioning that there is no protein-degrader based drug in the market yet. We can expect the therapy to become an extensive part of therapeutic modality in upcoming decade.


Comments

Popular posts from this blog

Marketing Strategy Consulting Firm At Rootsanalysis